Evidence map›Paper›PMID 41938743›Full record

ArticleBlood neoplasia2026

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and Beat AML 2024: a real-world AML validation study.

Tariq Kewan, Oudai Alkabbani, Hadil Zureigat, Rong He, Dragan Jevremovic, Patricia Greipp, Antoine Saliba, Aasiya Matin, Mehrdad Hefazi Torghabeh, Abishek Mangaonkar and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tariq KewanDepartment of Hematology, Mayo Clinic, Rochester, MN.
Oudai AlkabbaniDepartment of Hematology, Mayo Clinic, Rochester, MN.
Hadil ZureigatDepartment of Hematology, Mayo Clinic, Rochester, MN.
Rong HeDepartment of Hematology, Mayo Clinic, Rochester, MN.
Dragan JevremovicDepartment of Hematology, Mayo Clinic, Rochester, MN.
Patricia GreippDepartment of Hematology, Mayo Clinic, Rochester, MN.
Antoine SalibaDepartment of Hematology, Mayo Clinic, Rochester, MN.
Aasiya MatinDepartment of Hematology, Mayo Clinic, Rochester, MN.
Mehrdad Hefazi TorghabehDepartment of Hematology, Mayo Clinic, Rochester, MN.
Abishek MangaonkarDepartment of Hematology, Mayo Clinic, Rochester, MN.
Naseema GangatDepartment of Hematology, Mayo Clinic, Rochester, MN.
William HoganDepartment of Hematology, Mayo Clinic, Rochester, MN.
Mrinal PatnaikDepartment of Hematology, Mayo Clinic, Rochester, MN.
Hassan AlkhateebDepartment of Hematology, Mayo Clinic, Rochester, MN.
Cecilia Arana YiDepartment of Hematology, Mayo Clinic, Scottsdale, AZ.
James ForanDepartment of Hematology, Mayo Clinic, Jacksonville, FL.
Mark LitzowDepartment of Hematology, Mayo Clinic, Rochester, MN.
Mithun ShahDepartment of Hematology, Mayo Clinic, Rochester, MN.
Kebede BegnaDepartment of Hematology, Mayo Clinic, Rochester, MN.
Aref Al-KaliDepartment of Hematology, Mayo Clinic, Rochester, MN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Real-world validation of the European LeukemiaNet (ELN) 2022, ELN 2024, and Beat Acute Myeloid Leukemia (AML) 2024 across different therapies is needed. We evaluated 426 patients with AML (median age, 68 years; 60% male) treated from 2016 to 2025. ELN 2024 (55%, 24%, and 20%), ELN 2022 (20%, 20%, and 60%), and Beat AML 2024 (21%, 38%, and 41%) assigned patients to favorable-, intermediate-, and adverse-risk groups with variation. Less-intensive treatment (LIT) had lower complete remission (CR) odds than intensive chemotherapy (IC). For CR prediction, ELN 2022 (area under the receiver operating characteristic curve [AUC], 0.763) and Beat AML 2024 (AUC, 0.759) outperformed ELN 2024 (AUC, 0.718). With a median follow-up of 49.8 months, the median overall survival (mOS) was 15.7 months. Each system stratified mOS (all

Identifiers

PMID41938743
PMCPMC13050054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.